- Home
- TWG vs RLMD Comparison
TWG vs RLMD Comparison
Compare TWG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWG
- RLMD
- Stock Information
- Founded
- TWG 2009
- RLMD 2004
- Country
- TWG Hong Kong
- RLMD United States
- Employees
- TWG N/A
- RLMD N/A
- Industry
- TWG
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- TWG
- RLMD Health Care
- Exchange
- TWG NYSE
- RLMD Nasdaq
- Market Cap
- TWG 12.9M
- RLMD 11.5M
- IPO Year
- TWG 2024
- RLMD N/A
- Fundamental
- Price
- TWG $0.23
- RLMD $0.37
- Analyst Decision
- TWG
- RLMD Hold
- Analyst Count
- TWG 0
- RLMD 4
- Target Price
- TWG N/A
- RLMD $4.25
- AVG Volume (30 Days)
- TWG 1.5M
- RLMD 942.1K
- Earning Date
- TWG 02-15-2025
- RLMD 03-18-2025
- Dividend Yield
- TWG N/A
- RLMD N/A
- EPS Growth
- TWG N/A
- RLMD N/A
- EPS
- TWG 0.02
- RLMD N/A
- Revenue
- TWG $14,375,689.00
- RLMD N/A
- Revenue This Year
- TWG N/A
- RLMD N/A
- Revenue Next Year
- TWG N/A
- RLMD N/A
- P/E Ratio
- TWG $12.19
- RLMD N/A
- Revenue Growth
- TWG 21.97
- RLMD N/A
- 52 Week Low
- TWG $0.17
- RLMD $0.34
- 52 Week High
- TWG $13.50
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- TWG N/A
- RLMD 25.62
- Support Level
- TWG N/A
- RLMD $0.36
- Resistance Level
- TWG N/A
- RLMD $0.49
- Average True Range (ATR)
- TWG 0.00
- RLMD 0.06
- MACD
- TWG 0.00
- RLMD 0.08
- Stochastic Oscillator
- TWG 0.00
- RLMD 10.06
About TWG TOP WEALTH GROUP HLDG LTD
Top Wealth Group Holding Ltd is as supplier of caviar and offer caviar-based gourmet products. It is specialized in supplying high quality sturgeons caviar.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.